Lacey Smith

Lacey Smith

Auto-generated profile, based on publicly available information

Lacey Smith

Epilepsy Genetics Program, Department of Neurology, Boston Children’s Hospital, Boston, MA, 02115, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2022 in Journal of Genetic Counseling
Verified
Journal Article
Closed access
LSLacey Smith
Lacey Smith
JMJennifer Malinowski
Jennifer Malinowski
SCSophia Ceulemans
Sophia Ceulemans
KPKatlin Peck
Katlin Peck
NWNephi Walton
Nephi Walton
NLNatalie Lippa
Natalie Lippa

19 January 2020 in Epilepsia
Verified
Journal Article
Closed access
PDF file
ARAnne M. Rochtus
Anne M. Rochtus
HOHeather E. Olson
Heather E. Olson
LSLacey Smith
Lacey Smith
LKLouisa G. Keith
Louisa G. Keith
CAChristelle El Achkar
Christelle El Achkar
APAnnapurna Poduri
Annapurna Poduri

6 July 2020 in npj Genomic Medicine
Verified
Journal Article
Open access
PDF file
SRShira Rockowitz
Shira Rockowitz
NLNicholas LeCompte
Nicholas LeCompte
MCMary Carmack
Mary Carmack
AQAndrew Quitadamo
Andrew Quitadamo
LWLily Wang
Lily Wang
PSPiotr Sliz
Piotr Sliz
While genomic data is frequently collected under distinct research protocols and disparate clinical and research regimes, there is a benefit in streamlining sequencing strategies to create harmonized databases, particularly in the area of pediatric rare disease. Research hospitals seeking to implement unified genomics workflows for research and clinical practice face numerous challenges, as they need to address the unique requirements and goals of the distinct environments and many stakeholders, including clinicians, researchers and sequencing providers. Here, we present outcomes of the first phase of the Children’s Rare Disease Cohorts initiative (CRDC) that was completed at Boston Children’s Hospital (BCH). We have developed a broadly sharable database of 2441 exomes from 15 pediatric rare disease cohorts, with major contributions from early onset epilepsy and early onset inflammatory bowel disease. All sequencing data is integrated and combined with phenotypic and research data in a genomics learning system (GLS). Phenotypes were both manually annotated and pulled automatically from patient medical records. Deployment of a genomically-ordered relational database allowed us to provide a modular and robust platform for centralized storage and analysis of research and clinical data, currently totaling 8516 exomes and 112 genomes. The GLS integrates analytical systems, including machine learning algorithms for automated variant classification and prioritization, as well as phenotype extraction via natural language processing (NLP) of clinical notes. This GLS is extensible to additional analytic systems and growing research and clinical collections of genomic and other types of data.

18 November 2014 in Journal of Genetic Counseling
Verified
Journal Article
Closed access
PDF file
LSLacey A. Smith
Lacey A. Smith
JDJessica Douglas
Jessica Douglas
ABAlicia A. Braxton
Alicia A. Braxton
KKKate Kramer
Kate Kramer

6 January 2017 in Journal of Child Neurology
Verified
Journal Article
Closed access
PDF file
LSLacey A. Smith
Lacey A. Smith
JUJeremy F. P. Ullmann
Jeremy F. P. Ullmann
HOHeather E. Olson
Heather E. Olson
CAChristelle M. El Achkar
Christelle M. El Achkar
GTGessica Truglio
Gessica Truglio
APAnnapurna Poduri
Annapurna Poduri
Recent technological advances in gene sequencing have led to a rapid increase in gene discovery in epilepsy. However, the ability to assess pathogenicity of variants, provide functional analysis, and develop targeted therapies has not kept pace with rapid advances in sequencing technology. Thus, although clinical genetic testing may lead to a specific molecular diagnosis for some patients, test results often lead to more questions than answers. As the field begins to focus on therapeutic applications of genetic diagnoses using precision medicine, developing processes that offer more than equivocal test results is essential. The success of precision medicine in epilepsy relies on establishing a correct genetic diagnosis, analyzing functional consequences of genetic variants, screening potential therapeutics in the preclinical laboratory setting, and initiating targeted therapy trials for patients. The authors describe the structure of a comprehensive, pediatric Epilepsy Genetics Program that can serve as a model for translational medicine in epilepsy.

2 June 2026 in Genetics in Medicine
Verified
Journal Article
Open access
LSLacey Smith
Lacey Smith
EBEmily Bonkowski
Emily Bonkowski
APAnna Prentice
Anna Prentice
SCStacey Cohen
Stacey Cohen
LLLaina Lusk
Laina Lusk
HMHeather C. Mefford
Heather C. Mefford
Pathogenic variants in SCN1A, SCN2A, SCN3A, SCN8A, and SCN1B have been associated with a spectrum of epilepsy and neurodevelopmental disorders. We created a ClinGen Variant Curation Expert Panel and adapted the ACMG/AMP recommendations for sequence variant classification for each of these genes. We convened a multidisciplinary panel and evaluated current recommendations for applicability. We generated specifications based on clinical, bioinformatic, and functional data, and piloted modified criteria on 37 variants. Our pilot consisted of variants across the spectrum of prior classifications (pathogenic, benign and variant of uncertain significance) and range of variant types (missense, nonsense, frameshift, and intronic). Through iterative discussion, our specifications notably include 1) importance of epilepsy syndrome classification and phenotyping, 2) optimization of population thresholds (BS1, BA1), 3) use of paralogous genes when considering prior pathogenic variants at corresponding positions (PS1, PM5), and 4) guidance on interpreting functional data (PS3), among other modifications. Adopting modified variant curation specifications for SCN1A, SCN2A, SCN3A, SCN8A, and SCN1B optimizes variant classification based on evolving knowledge of sodium channel genes. Obtaining an accurate genetic diagnosis has both clinical and personal utility for individuals living with epilepsy and neurodevelopmental disorders, particularly as precision therapeutics become more widely available.